Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, which is used for the treatment of schizophrenia, enhancing the company's product pipeline and supporting sustainable development [1] Company Summary - Qianjin Xiangjiang Pharmaceutical, a subsidiary of Qianjin Pharmaceutical, has invested a total of 6.3294 million yuan in the research and development of Lurasidone Hydrochloride Tablets [1] - The approval of Lurasidone Hydrochloride Tablets signifies that the product has passed the consistency evaluation, which is a positive development for the company's product offerings [1] Industry Summary - Other companies that have received the drug registration certificate for Lurasidone Hydrochloride Tablets include Jiangsu Hengrui Medicine Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., and Zhejiang Haizheng Pharmaceutical Co., Ltd. [1] - The production and sales of the drug are subject to significant uncertainties due to factors such as national policies and market environment changes [1]

Core Viewpoint - Qianjin Pharmaceutical's subsidiary, Qianjin Xiangjiang Pharmaceutical, has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant milestone in the company's product pipeline and potential for sustainable development [1] Group 1: Drug Registration and Development - The drug is indicated for the treatment of schizophrenia, with other companies such as Jiangsu Hengrui Medicine Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. also having obtained registration for the same drug [1] - Qianjin Xiangjiang Pharmaceutical has invested a total of 6.3294 million yuan in the research and development of Lurasidone Hydrochloride Tablets [1] Group 2: Market and Regulatory Environment - The approval of the drug registration certificate is considered equivalent to passing the consistency evaluation, which enhances the company's product offerings [1] - The production and sales of the drug are subject to significant uncertainties due to potential changes in national policies and market conditions [1]

证券日报网讯 12月10日，千金药业在互动平台回答投资者提问时表示，公司一直与包括机构股东在内 的投资者保持良好交流，传递公司价值。 （文章来源：证券日报） ...

Core Viewpoint - Qianjin Pharmaceutical (600479) confirmed that during the transition period of its acquisition plan, any profits or increases in net assets from the target company will be enjoyed by the listed company [1] Group 1 - The company responded to investor inquiries on an interactive platform regarding its acquisition plan [1] - The increase in investment income for the company in the third quarter was attributed to the investment returns from its stake in the Guohai Guochuang Pharmaceutical Fund [1]

Group 1 - The core viewpoint of the article is that Qianjin Pharmaceutical clarified that the profits from the acquisition of certain equity stakes will not be included in the net profit attributable to the parent company in the financial report for the third quarter of 2025 [1] - The financial profits from the two equity acquisitions will start to be consolidated in the financial statements in October and November 2025 respectively [1]

每经AI快讯，有投资者在投资者互动平台提问：公司有无流感相关仿制药的立项？ 千金药业（600479.SH）12月10日在投资者互动平台表示，公司有治疗流感相关仿制药立项。 （记者 张明双） ...

关于发行股份及支付现金购买资产暨关联交易 证券代码：600479 证券简称：千金药业 公告编号：2025-060 株洲千金药业股份有限公司 根据上述专项审计报告，在本次交易的过渡期间内，千金湘江药 业实现净利润 135,203,152.10 元，千金协力药业实现净利润 35,252,082.95 元，标的资产均未出现经营亏损，交易对方无需承担 补偿责任，标的资产在过渡期内产生的收益由千金药业享有。 之标的资产过渡期损益情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 株洲千金药业股份有限公司（以下简称"千金药业"或"公司"） 以发行股份及支付现金方式购买湖南千金湘江药业股份有限公司（以 下简称"千金湘江药业"）28.92%的股权及湖南千金协力药业有限公 司（以下简称"千金协力药业"）68.00%的股权（以下简称"本次交 易"）。本次交易的标的资产已全部完成交割过户，公司为支付标的资 产对价新发行的股份已完成上市，现将本次交易标的资产过渡期间损 益相关情况公告如下： 一、关于过渡期损益安排 根据公司与交易各方签订的《附 ...

目 录 | 一、专项审计报告…………………………………………………… | 第 1—3 | 页 | | --- | --- | --- | | 二、资产交割过渡期利润表………………………………………………第 | | 4 页 | | 三、财务报表附注…………………………………………………… | 第 5—27 | 页 | | 四、附件……………………………………………………………第 | 28—31 | 页 | | （一）本所营业执照复印件 …………………………………… | 第 28 | 页 | | （二）本所执业证书复印件 …………………………………… | 第 29 | 页 | | （三）本所签字注册会计师执业证书复印件 ………………第 | 30-31 | 页 | 关于湖南千金湘江药业股份有限公司 过渡期损益情况的专项审计报告 天健审〔2025〕2-499 号 湖南千金湘江药业股份有限公司全体股东： 一、审计意见 我们审计了湖南千金湘江药业股份有限公司（以下简称湘药公司）资产交割 过渡期（2024 年 10 月 1 日至 2025 年 9 月 30 日）的利润表以及相关附注（以下 合称财务报表）。 我们认为，后附的 ...

目 录 | 一、专项审计报告………………………………………………………第 | 1—3 | 页 | | --- | --- | --- | | 二、资产交割过渡期利润表………………………………………………第 | 4 | 页 | | 三、财务报表附注……………………………………………………第 | 5—25 | 页 | | 四、附件………………………………………………………………第 | 26—29 | 页 | | （一）本所营业执照复印件 ………………………………………第 | 26 | 页 | | （二）本所执业证书复印件 ………………………………………第 | 27 | 页 | | （三）本所签字注册会计师执业证书复印件…………………第 | 28—29 | 页 | 专项审计报告 天健审〔2025〕2-520 号 湖南千金协力药业有限公司全体股东： 一、审计意见 我们审计了湖南千金协力药业有限公司（以下简称千金协力药业公司）资产 交割过渡期（2024 年 10 月 1 日至 2025 年 10 月 31 日）的利润表以及相关附注 （以下合称财务报表）。 我们认为，后附的财务报表在所有重大方面按照财务报表附注三所述的编 ...

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].